A "drug-carrier homologation" cardiac patch for myocardial infarction therapy via month-long controlled H2S release.

Hydrogen sulfide (H2S), a gaseous signaling molecule with multiple cardioprotective effects, has attracted considerable attention for treating myocardial infarction (MI), a leading global cause of death. However, its ultrashort half-life (seconds to…

Preview only. Read the full abstract at the source